Factors predicting low patient accrual in cancer clinical trials
A partir de données portant sur 787 essais de phase II/III lancés par un groupe coopérateur du National Cancer Institute entre 2000 et 2011, cette étude identifie un ensemble de facteurs associés à une faible inclusion de patients
Nearly one in four publicly sponsored cancer clinical trials fail to enroll enough participants to draw valid conclusions about treatments or techniques. Such trials represent a waste of scarce human and economic resources and contribute little to medical knowledge. Although many studies have investigated the perceived barriers to accrual from the patient or provider perspective, very few have taken a trial-level view and asked why certain trials are able to accrue patients faster than expected while others fail to attract even a fraction of the intended number of participants. According …